Edgen Stock·Sep 25 2025, 21:05返回
返回
Intellia Therapeutics報告Nexiguran Ziclumeran治療ATTRv-PN的積極長期1期數據
Edgen Stock·Sep 25 2025, 21:05
[1] Intellia強調實驗藥物單次給藥的臨床改善 (https://finance.yahoo.com/news/intellia-highl ...)[2] Amvuttra的卓越表現推高Alnylam的業績指引和股價 - FirstWord Pharma (https://vertexaisearch.cloud.google.com/groun ...)[3] Intellia Therapeutics公佈Nexiguran Ziclumeran (nex-z)治療遺傳性轉甲狀腺素蛋白(ATTR)澱粉樣變性伴多發性神經病變患者的積極長期1期數據 (https://vertexaisearch.cloud.google.com/groun ...)